Beam Therapeutics Inc.

Eli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn

Jacob Rubens was supposed to be paying attention in his chemistry lecture. Instead, flipping through Rolling Stone, he stumbled upon an interview that would alter the trajectory of his life. “I was re

Verve Therapeutics is looking to submit its opt-in package to partner Eli Lilly after the announcement of positive data from the Phase Ib study of VERVE-102 in heterozygous familial hypercholesterolem

News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b